

DAFTAR PUSTAKA

1. Bittencourt RI, Vassallo J, Chauffaille M de LLF, Xavier SG, Pagnano KB, Nascimento ACK, et al. Philadelphia-negative chronic myeloproliferative neoplasms. *Rev Bras Hematol Hemoter.* 2012;34(2):140–9.
2. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms. *Leukemia.* 2008;22(1):14–22.
3. Barbui T, Thiele J, Gisslinger H. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. *Blood Cancer J [Internet].* 2018;8(2):15. Available from: <http://dx.doi.org/10.1038/s41408-018-0054-y>
4. Rumi E, Cazzola M. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. *Blood.* 2017;129(6):680–92.
5. Elbager S, Bayoumi M. Clinical Manifestations of Philadelphia-negative Myeloproliferative Neoplasms in Sudan. 2018;4(June):98–195.
6. Yassin MA, Taher A, Mathews V, Hou HA, Shamsi T, Tuğlular TF, et al. MERGE: A Multinational, Multicenter Observational Registry for Myeloproliferative Neoplasms in Asia, including Middle East, Turkey, and Algeria. *Cancer Med.* 2020;9(13):4512–26.
7. Samer A S, Susan S D, Lindsay M M. Incidence and Patient Survival of Myeloproliferative Neoplasms (MPNs) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPNs) in the United States: A Population-Based View of the Modern Diagnostic Era. *Am Soc Hematol.* 2015;126(23):2806.
8. Yap YY, Law KB, Sathar J, Lau NS, Goh AS, Chew TK, et al. The epidemiology and clinical characteristics of myeloproliferative neoplasms in Malaysia. *Exp Hematol Oncol [Internet].* 2018;7(1):1–12. Available from: <https://doi.org/10.1186/s40164-018-0124-7>
9. Shallis RM, Wang R, Davidoff A, Ma X, Podoltsev NA, Zeidan AM. Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map. *Blood Rev [Internet].* 2020;42:100706. Available from: <https://doi.org/10.1016/j.blre.2020.100706>

10. Sukrisman L. Trombosis Vena dan Arteri pada Myeloproliferative Neoplasms. *J Penyakit Dalam Indones.* 2019;6(3):129.
11. Meier B, Burton JH. Myeloproliferative Disorders. *Hematol Clin NA* [Internet]. 2017;31(6):1029–44. Available from: <https://doi.org/10.1016/j.hoc.2017.08.007>
12. Accurso V, Santoro M, Raso S, Contrino AD, Casimiro P, Di Piazza F, et al. Splenomegaly impacts prognosis in essential thrombocythemia and polycythemia vera: A single center study. *Hematol Rep.* 2019;11(4):95–7.
13. Maffioli M, Mora B, Passamonti F. Polycythemia vera: From new, modified diagnostic criteria to new therapeutic approaches. *Clin Adv Hematol Oncol.* 2017;15(9):700–7.
14. Saktini F, Santosa S, Faradz SM. JAK2 V617F Analysis in Indonesian Myeloproliferative Neoplasms Patients. *J Biomed Transl Res.* 2015;1(2):27.
15. Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management. *Am J Hematol.* 2017;92(1):94–108.
16. Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: An international study. *Leukemia.* 2013;27(9):1874–81.
17. Passamonti F, Rumi E, Pungolino E, Malabarba L, Bertazzoni P, Valentini M, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. *Am J Med.* 2004;117(10):755–61.
18. Haider M, Gangat N, Lasho T, Abou Hussein AK, Elala YC, Hanson C, et al. Validation of the revised international prognostic score of thrombosis for essential thrombocythemia (IPSET-thrombosis) in 585 Mayo clinic patients. *Am J Hematol.* 2016;91(4):390–4.
19. Maria HDS, Service N, Maria HDS. Chronic myeloproliferative diseases. 2014;120.
20. Levine RL, Gilliland DG. ASH 50th anniversary review Myeloproliferative disorders Early investigation. 2019;112(6):2190–9.
21. Vannucchi AM, Barbui T, Cervantes F, Harrison C, Kiladjian JJ, Kröger N, et al. Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* [Internet]. 2015;26(August):v85–99. Available from:



<http://dx.doi.org/10.1093/annonc/mdv203>

22. Pasquier F, Cabagnols X, Secardin L, Plo I, Vainchenker W. SOHO Supplement 2014 Myeloproliferative Neoplasms : JAK2 Signaling Pathway as a Central Target for Therapy. *Clin Lymphoma, Myeloma Leuk* [Internet]. 2014;14(September):S23–35. Available from: <http://dx.doi.org/10.1016/j.clml.2014.06.014>
23. Vainchenker W, Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. *Blood*. 2017;129(6):667–79.
24. Oh ST, Simonds EF, Jones C, Hale MB, Goltsev Y, Gibbs KD, et al. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. *Blood*. 2010;116(6):988–92.
25. Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, et al. Europe PMC Funders Group Somatic CALR Mutations in Myeloproliferative Neoplasms with. *N Engl J Med*. 2014;369(25):2391–405.
26. Moulard O, Mehta J, Fryzek J, Olivares R, Iqbal U, Mesa RA. Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union. *Eur J Haematol*. 2014;92(4):289–97.
27. Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. *N Engl J Med*. 2013;369(25):2379–90.
28. Song M, Park B, Uhm J. Understanding Splenomegaly in Myelofibrosis : Association with Molecular Pathogenesis. 2018;
29. Stein BL, Rademaker A, Spivak JL, Moliterno AR. Gender and Vascular Complications in the JAK2 V617F-Positive Myeloproliferative Neoplasms. 2011;2011.
30. Landolfi R, Gennaro L Di. Pathophysiology of thrombosis in myeloproliferative neoplasms few answers and many new questions. 2011;96(2):183–6.
31. Mehta J, Wang H, Iqbal SU, Mesa R. Epidemiology of myeloproliferative neoplasms in the United States. *Leuk Lymphoma*. 2014;55(3):595–600.
32. Byun JM, Kim YJ, Youk T, Yang JJ, Yoo J, Park TS. Real world epidemiology of myeloproliferative neoplasms: a population based study in Korea 2004–2013. *Ann Hematol*. 2017;96(3):373–81.
33. Szuber N, Mudireddy M, Nicolosi M, Penna D, Vallapureddy RR, Lasho TL, et al. 3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-

Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups. *Mayo Clin Proc* [Internet]. 2019;94(4):599–610. Available from: <https://doi.org/10.1016/j.mayocp.2018.08.022>

34. Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. *Br J Haematol*. 2005;128(3):275–90.
35. Carobbio A, Antonioli E, Guglielmelli P, Vannucchi AM, Delaini F, Guerini V, et al. Leukocytosis and risk stratification assessment in essential thrombocythemia. *J Clin Oncol*. 2008;26(16):2732–6.



Lampiran


 KEMENTERIAN PENDIDIKAN DAN KEBUDAYAAN
 UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
 KOMITE ETIK PENELITIAN KESEHATAN
 RSPTN UNIVERSITAS HASANUDDIN
 RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
 Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
 JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.
 Contact Person: dr. Agussalim Bukhari, MMed, PhD, SpGK. TELP. 081241850858, 0411 5780103, Fax : 0411-581431
 

REKOMENDASI PERSETUJUAN ETIK
 Nomor : 187/UN4.6.4.5.31/ PP36/ 2020

Tanggal: 25 Februari 2020

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH20020131	No Sponsor	
Peneliti Utama	dr. Muh Junaedi	Protokol	
Judul Peneliti	Kesintasan Penderita Myeloproliferatif Neoplasma Berdasarkan Stratifikasi Risiko		
No Versi Protokol	1	Tanggal Versi	20 Februari 2020
No Versi PSP		Tanggal Versi	
Tempat Penelitian	RSUP Dr.Wahidin Sudirohusodo dan RS Jejaring Makassar		
Jenis Review	<input checked="" type="checkbox"/> Exempted <input type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal	Masa Berlaku 25 Februari 2020 sampai 25 Februari 2021	Frekuensi review lanjutan
Ketua Komisi Etik Penelitian Kesehatan FKUH	Nama Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)	Tanda tangan	
Sekretaris Komisi Etik Penelitian Kesehatan FKUH	Nama dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)	Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari protokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan